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HF; Heart Failure 
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propenamide or Tyrphostin AG 825, a selective ErbB2 inhibitor 
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FS; Fraction Shortening 
MyBP-C; cardiac Myosin Binding Protein C 






Altered Serine/Threonine phosphorylation of the cardiac proteome is an established 
hallmark of heart failure (HF). However, the contribution of tyrosine phosphorylation to 
the pathogenesis of these diseases remains unclear. The cardiac proteome was explored 
by global mapping to discover and quantify site-specific tyrosine phosphorylation in two 
cardiac hypertrophic models; cardiac overexpression of ErbB2 (TgErbB2) and cardiac 
expression of a-Myosin heavy chain R403Q (R403Q-aMyHCTg) compared to control 
hearts. Phosphoproteomic changes found in R403Q-aMyHC Tg mice indicated EGFR1, 
Focal Adhesion, VEGF, ErbB signaling, and Chemokine signaling pathways activity were 
likely to be activated. On the other hand, TgErbB2 mice findings displayed significant 
overrepresentation of Right Ventricular Cardiomyopathy, Hypertrophic Cardiomyopathy 
(HCM), and dilated cardiomyopathy (DCM) KEGG Pathways. In silico kinase-substrate 
enrichment analysis (KSEA) highlighted a marked downregulation of canonical MAPK 
Pathway Activity downstream of k-Ras in TgErbB2 mice and activation of EGFR, PP2 
inhibition of c-Src, and Hepatocyte growth factor stimulation. In vivo ErbB2 inhibition by 
AG-825 decreased cardiac fibrosis, cardiomyocyte disarray, and rescued contractile 
function on TgErbB2 mice. These results suggest that altered tyrosine phosphorylation 
may play a regulatory role in cardiac hypertrophic models, suggesting that tyrosine kinase 








Familial hypertrophic cardiomyopathy (HCM) increases the left ventricle (LV) wall 
thickness and cannot be explained by abnormal loading conditions. Mutations in genes 
encoding for sarcomeric proteins are common in HCM patients (40-60%)1. Studying post-
translational modifications (PTMs) of sarcomeric (or Ca2+ handling proteins) can offer a 
unique opportunity to understand better how genetic disorders lead to cardiac dysfunction 
and discover potential targets for therapy 2-4. For instance, PTMs of cardiac Troponin I 
(cTnI), a sarcomere protein that is centrally involved in myocardial contractility regulation, 
have been extensively studied, particularly for the functional role of PKA-dependent 
phosphorylation5. Notably, phosphorylation of cTnI-S22/23 - one of the most relevant 
regulatory sites of cTnI – is known to be down-regulated in human heart failure (HF)6 and 
leads to contractile dysfunction 7. 
Tyrosine phosphorylation is essential for cardiac structural development and 
myofibril organization during embryogenesis8,9. For example, several tyrosine 
phosphatases have been linked to heart disease and even proposed as a therapeutic 
target for some conditions. Moreover, mutations at the level of tyrosine-protein 
phosphatase non-receptor type 11 (PTPN11) can lead to HCM or dilated cardiomyopathy 
(DCM)10,11. In the heart, PTPN11 likely plays a role in systolic dysfunction produced by 
pressure-overload12. Another tyrosine phosphatase is associated with cardiac 
pathophysiology, specifically acid phosphatase 1 (ACP1):—the deletion of ACP1 results 
in a protection against stress-induced cardiomyopathy 13. Our group first showed that 
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cTnI-Y26 phosphorylation is readily detected in healthy human hearts and down-
regulated in human HF and DCM 14. However, how these alterations contribute to the 
onset and progression of cardiac disease remains poorly understood. A better grasp of 
additional site-specific changes of individual pTyr sites would help in this direction, 
substantially.  
 In the present study, a label-free and tandem mass tagging (TMT) quantitative 
global phosphotyrosine proteomics approach was applied to determine which sarcomeric 
sites have altered amounts of Tyr phosphorylation at specific sites in two unrelated 
models of HCM. The first model is secondary to the overexpression of the tyrosine kinase 
receptor ErbB215,16; the second recapitulates features of the human disease, more 
specifically, an R403Q mutation of the myofilament protein myosin heavy chain, 
distinctive of familial hypertrophic cardiomyopathy17. The rationale for this choice was to 
determine whether triggering HCM through different mechanisms elicits similar, pTyr-
related pathways/regulatory sites within the heart. In doing so, the manipulation of these 
Tyrosine phosphorylation sites can offer new opportunities for therapeutic targeting in 
different forms of human HCM  
 
RESULTS  
Choice of the Models 
The approach combined examination of the global proteome and myofilament targeted 
tyrosine phosphorylation proteomics approach in two HCM mice models to identify the 
potential impact of altered Tyr phosphorylation on underlying disease mechanisms. One 
model has HCM caused by cardiac-specific overexpression of a tyrosine kinase receptor 
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(ErbB2); the second is a classic model of a point mutation in a significant sarcomeric 
protein (R403Q-aMyHC mice). TgErbB2 mice initially develop a striking, concentric 
cardiac hypertrophy, which evolves to diffuse fibrosis and myocyte disarray 16 with HCM. 
This line of mice also has abnormal calcium handling, and are prone to arrhythmias and 
develop Hypertrophic Obstructive Cardiomyopathy 2. Similarly, R403Q-aMyHC mice 
reproduce human familial HCM by progressing from mild hypertrophy, mild fibrosis to 
frank myocyte disarray, HF, and arrhythmias 17.  
 
Immunoblotting Reveals Increased Cardiac Tyrosine Phosphorylation in HCM 
models 
First, immunoblot analysis of the myocardium of TgErbB2 and Ntg mice for tyrosine 
phosphorylation was applied. In the whole heart homogenates of ErbB2 overexpressing 
mice, there was a global increase of Tyrosine phosphorylation compared to non-
transgenic (Ntg) littermates (Fig.1A). These findings were corroborated with an immuno-
blot using pan-tyrosine phosphorylated antibodies detected by a fluorescent secondary 
and normalizing the tyrosine phosphorylation signal to Troponin I levels (Fig.1B). 
Although c-Src (proto-oncogene tyrosine-protein kinase Src) is downstream of ErbB2 
signaling, we did not anticipate its increased expression in TgErbB2 mice (Fig1.C, D) 
when normalized to GAPDH signals. The c-Src activity was enhanced in TgErbB2 mice 
compared to Ntg, as revealed by enhanced Tyr416 phosphorylation (Fig.1E). Altogether 
these data suggest that tyrosine phosphorylation is a broadly distributed post-translational 
modification (PTM) in the myocardium. Therefore, alterations in cardiac tyrosine 
phosphorylation may play a regulatory role in the disease progression of non-ischemic 
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cardiomyopathies, such as familial cardiomyopathy (HCM) and dilated cardiomyopathy 
(DCM), as part of the pathophysiologic response to the underlying disease. 
 
Tyrosine phosphorylation in myofilaments and cross-talk with serine/threonine 
kinases/phosphatases  
A label-free phospho-tyrosine proteomics approach was undertaken to compare the 
cardiac tyrosine phosphorylation profile of Non-transgenic controls (Ntg), TgErbB2, and 
R403Q-aMyHC mice (Fig.2). It was hypothesized that unbiased global pTyr profiling 
would yield salient information about which specific tyrosine sites are phosphorylated in 
well-known essential cardiac-specific proteins and tyrosine kinases, thus providing clues 
about which tyrosine kinases could be mediating cardiac tyrosine phosphorylation. A total 
of 1,800 peptide spectra matched (PSM) were collected from the heart ventricle whole 
proteome, and 50% were identified with high confidence resulting in 431 unique tyrosine-
phosphorylated peptides corresponding to 239 proteins. Tables with all identified 
phosphoproteins and phosphopeptides are provided in Supplementary Table 1-7. An 
evaluation of the MS data quality, intensity, and distribution post-median sweep 
normalization are shown in Supplementary Fig.S1. Confidence of Phosphorylated site 
localization was evaluated for annotation, and a score of more than 49% was required.  
This data set indicates that a comparable yield of peptide identification was achieved, 
reproducibility on the enrichment of pTyr peptides, and high-quality MS/MS data using 
similar approaches to others 18-20. 
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The label-free phospho-tyrosine proteomics approach core findings identified 239 
different tyrosine-phosphorylated proteins, 169 tyrosine-phosphorylated proteins that 
overlap among the control mouse hearts (Ntg), and the myocardium from two cardiac 
hypertrophic models (TgErbB2 and R403Q-aMyHC). At the peptide level, 431 pTyr sites 
were detected with an overlap of 271 tyrosine phosphorylated residues (Fig.2E, F). Also, 
18 novel pTyr sites were detected with an overlap of 13 pTyrosine sites for the three 
mouse groups (Fig.2G). These are novel sites not reported before, nor found in the 
extensively curated database PhosSitePlus (Cell Signaling Technology). 
Next, the focus was on the cardiac-specific proteins from the myofilament apparatus. Nine 
major myofilament proteins were tyrosine phosphorylated. They harbor multiple tyrosine 
phosphorylation sites, many of which are novel (See Supplementary Fig.S2); the best 
example is Titin with 36 pTyr sites (See Supplementary Fig.S3). Also, seventeen tyrosine 
kinases had detectable tyrosine phosphorylation sites, and thus they could potentially be 
involved in regulating cardiac myofilament tyrosine phosphorylation. 
In contrast, only two tyrosine phosphatases (Ptpn11 and Ptpra) demonstrated 
detectable tyrosine phosphorylation sites and, therefore, are likely to play a role in 
regulating cardiac tyrosine phosphorylation levels in the sarcomere. In addition to the 
number of tyrosine kinases found with pTyr sites, fifteen serine/threonine kinases had 
detectable tyrosine phosphorylation sites; however, only one serine/threonine 
phosphatase (Ppp1r12b) demonstrated tyrosine phosphorylation sites. These data show 
that cardiac myofilament tyrosine phosphorylation is broadly distributed and that there 




ErbB2 Cardiac Overexpression and R403Q-aMyHC Point Mutation Remodeled the 
Cardiac Tyrosine Phosphorylation Proteome 
 
Next, studies were undertaken to define the impact of ErbB2 cardiac overexpression and 
R403Q mutation of the cardiac myosin heavy chain on the specific tyrosine 
phosphorylation changes.  Data were then analyzed to determine the signaling 
transduction pathways associated with two unrelated types of HCM. Spectral 
normalization and statistical methods were performed, as previously described 21,22.  
Then, principal component analysis (PCA), k-means and hierarchical clustering were 
applied to determine if the pTyr profiles were similar within the groups. This approach 
determined that, indeed, the three groups segregate distinctively by the principal 
component 1 (PC1= 36.6%), whereas no group-wise distinction was evident in the second 
component (PC2=16.4%), see Fig.3A. Of note, one technical/biological replicate of 
R403Q-aMyHC was removed because it had more than 50% of absent pTyr peptides 
compared to the other two replicates. Hence, it was considered a technical failure. 
Heatmaps of hierarchically clustered up- or down-regulated pTyr peptides helped 
visualize the technical reproducibility and the specificity of how the genotype of cardiac 
hypertrophy largely influenced the phospho-tyrosine proteome remodeling (Fig.3B, 
p<0.05 by ANOVA). Tyrosine phosphorylated peptides are color-coded according to their 
extracted chromatogram MS1 signal intensities; yellow is upregulated, and blue is 
downregulated. This approach is a relative measure for peptide abundance. Additionally, 
k-means, which is an unsupervised machine learning algorithm, discovered the 
 10 
underlying pattern, which is distinct to every group, see the clusters in Fig.3C (p < 0.05), 
as opposed to having a flat upregulated (green) or downregulated (red) line among the 
three groups. These results demonstrate that Ntg, TgErbB2, and R403Q-aMyHC mice 
each have a pTyr proteome with a distinct signature, evidenced by PCA, heatmaps 
clustering, and k-means analysis; all of which are unsupervised unbiased statistical 
methods.     
 
Statistically significant changes (Log2 fold change > 1, p-value<0.05) were detected in 28 
phosphosites corresponding to 24 proteins in TgErbB2 mice (Fig.3D) and 77 
phosphosites in 57 proteins in the R403Q-aMyHC Tg mice (Fig.3F) using ANOVA (p < 
0.05). It is noteworthy that cardiac sarcomeric actin Y-200 was hyperphosphorylated 
(Log2 FC 1.11, p < 0.05) while cardiac Troponin I Y-113 was hypophosphorylated (Log2 
FC -2.73, p < 0.05) on R403Q-αMyHC mice hearts. The statistically significant pTyr 
changes observed in both animal models were subjected to pathway analysis (Ingenuity 
Pathway Analysis, Qiagen®). However, IPA has well-known disadvantages since the 
results have to be subjectively interpreted by the user 23. Statistical changes in proteins 
that match the phospho-tyrosine peptides do not account for the up-regulation or down-
regulation of a peptide and how that impacts activation or inhibition of their activity within 
their respective pathway. The analysis yielded significant results about over-represented 
canonical pathways and their upstream master regulators (B-H corrected p < 0.05). Such 
as Tec Kinase Signaling, VEGF, integrin-linked kinase (ILK), Rho family GTPase, PAK, 
CXCR4, actin cytoskeleton, and cardiac hypertrophy signaling pathway for R403Q-
aMyHC Tg mice, whereas that for TgErbB2 mice also actin cytoskeleton, ILK and 
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Synaptogenesis signaling pathway (Supplementary Fig.S4). However, since there are 
many pathways and potential master regulators, it is difficult to infer the precise biological 
significance. The complete list of upstream regulators is displayed in Supplementary 
tables 8 and 9 of Online Supplementary Data.  
 
To circumvent  IPA limitations, PhoshoEnrichment Software was used, which utilizes the 
Molecular Signatures Database (MsigDB) 24. This database was created by the Broad 
Institute that comprehends a well-curated collection of annotated gene data sets. Also, a 
novel database of PTM site-specific phosphorylation signatures of kinases, perturbations, 
and signaling pathways (PTMsigDB) was employed. PTMSigDB was recently developed 
by the Broad Institute 25. This tool accounts for phospho site-specific changes and their 
impact on activation or inhibition of a given pathway, together with the most common 
experimental Systems Biology Perturbations. The advantage of these bioinformatics tools 
is to assess the statistical significance of each pathway and Perturbation (gene-level and 
site-level) using a hypergeometric test. Here, the number of identified phosphosites and 
genes is used as the population for the hypergeometric model parameter instead of using 
all known genes as the population, as in IPA.  
 
A pathway enrichment analysis was performed on significant genes/sites (Log2 FC>1 and 
p-value < 0.05) using a gene-protein level with MSigDB. It was found that TgErbB2 mice's 
most significant pathways by KEGG are right ventricular cardiomyopathy (ARVC), see 
Fig.3D, E in pink color highlights, followed by hypertrophic cardiomyopathy (HCM) and 
dilated cardiomyopathy (DCM). Both Tg animal models showed a remarkable alteration 
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in Plakophilin-2 (PKP2) phosphorylation at the site Y119, although in TgErbB2 hearts, it 
was downregulated, and in R403Q-aMyHC Tg hearts, it was upregulated. Plakophilin-2 
(PKP2) is a critical component of the myocardium's desmosomes, and mutations in the 
gene encoding for this protein are associated with arrhythmogenic cardiomyopathy 26-28, 
suggesting that disturbed phosphorylation could have a functional impact.  
 
In comparison, the PTMsigDB revealed that pathway analysis at the phosphorylated site-
specific level did not reach statistical significance for the EGFR1 pathway. In the case of 
TgErbB2 mice, only three site-specific phosphosites matched the EGFR1 pathway; they 
are highlighted in cyan color at the Volcano plot (Fig.3D) and PTMsigDB table (Fig.3E). 
Intriguingly, however, in R403Q-aMyHC mice, the same pathway was statistically 
significant; see the 16 site-specific changes that matched the EGFR1 pathway (p=0.001) 
represented in the volcano plot as cyan data points (Fig.3F) and PTMsigDB table (Fig. 
3G). EGFR1 is a receptor tyrosine kinase, and the following most significant change is a 
signature secondary to Erythropoietin (PSP_EPO) stimulation (p= 5.6-4); see three purple 
and one blue data points on the volcano plot (Fig.3F), the blue dot is to show an 
overlapping site, Stat5a Y694p, of EGFR1 pathway and PSP_EPO (Erythropoietin 
stimulation). These data show the utility of phosphorylation site-specific databases to 
narrow the search of a biologically relevant pathway on phospho-proteomics data sets, 
particularly in understudied phosphorylation events such as pTyr that have small data 
sets to date. 
 
TMT Labeled Quantitative Proteomics of TgErbB2 Confirms Cardiac Sarcomere 
Tyrosine Phosphoproteome Dysregulation 
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A tandem mass tagging (TMT) quantitative labeling proteomics was used to gain more 
specific insight into the myofilament tyrosine phosphorylation changes. The hypothesis is 
that myofilament enrichment would enhance site-identification in myofilament proteins, 
specifically those with low abundance phospho-Tyrosine modifications, that may have 
been missed using the global approach. To that end, Ntg and TgErbB2 mice were 
evaluated using freshly isolated myofilaments, as described previously29 with minor 
modifications, from three hearts per genotype and evaluated the tyrosine 
phosphoproteome (Fig.4A, B), as described previously for the Heart Failure 
phosphoproteome20. Briefly, in this 6-plex TMT experiment, the peptides identified with 
single spectra were removed, which lead to 24,727 peptide spectra matched (PSM). After 
median sweep normalization, there were 1,116 peptides that corresponded to 1,092 
proteins. For spectral intensity distribution, before and after normalization, see 
Supplementary Fig.S5.  For pTyr Proteome 4,391 PSM were collected and followed the 
same quality control curation of the full proteome to remove missing data and unique 
spectra, which led to 3,064 PSM. Raw data of pTyr proteome spectral intensity distribution 
and PCA are shown in Supplementary Fig. S6A.  After median sweep normalization, 832 
peptides corresponded to 184 different proteins. Specific tyrosine phosphorylation for 146 
peptides was quantified because they had corresponding peptides from the full 
proteome's expression data. For further statistical data analysis, a workflow similar to that 
used for Label-Free proteomics was adopted. The only difference was that specific 
phosphorylation levels were calculated matching pTyr peptides intensity levels to their 
respective protein intensity levels on the flow-through fraction of peptides used for full 
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proteome determination and unsupervised statistical analysis obviated k-means because 
it is designed for experimental groups of three or more.  
The first step of the analysis uses unsupervised principal component analysis 
(PCA) and hierarchical clustering. PCA analysis showed the correlation between 
members in the same group and the ellipse represent the confidence interval of 95% (See 
Fig.5A, B, C), full proteome, pTyr proteome, and normalized pTyr proteome segregate 
well along PC1, showing a correlation of expression of 53.9%, 47.2%, and 57%, 
respectively. Heatmaps of hierarchically clustered expression helped to easily visualize 
how TgErbB2 cardiac overexpression largely influenced the genotype clustering. Both 
patterns, proteins from the full proteome (Fig.5D), and the normalized intensity of pTyr 
Proteome (Fig.5E) suggested a mirrored remodeling (377 proteins for full proteome and 
51 pTyr peptides had a p < 0.05 by LIMMA moderated 2-sample t-test comparison). 
From the full proteome, 1116 peptides were detected, which corresponded to 1092 
proteins. A comparison of the Log2 fold-change (FC) of TgErbB2/Ntg showed 377 proteins 
with statistically significant differences (Log2 FC >1 and p-value <0.05). Similar to label-
free proteome data, the statistically significant protein expression changes were 
subjected to MSigDB for pathway analysis, and their results are shown in Supplementary 
Table 10.  
To analyze specific pTyr Proteome specific phosphorylation, or normalized pTyr 
proteome, 146 phospho-sites that corresponded to 50 proteins were used, and the 
TgErbB2 mice showed significant changes in 21 pTyr sites (Fig.5G) that corresponded to 
15 proteins. Of note, a significant increase of pTyr was detected on MLC1-Y82,139, 
Myh6-Y1310, a-Tm-Y261, Actin-Y168, MyBP-C-Y544, and Actinin2-Y200, among other 
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proteins. Once again, a pathway enrichment analysis was performed using MsigDB on 
the 15 proteins representing the 21 pTyr sites, and as in the case of the label-free 
approach, TgErbB2 mice most significant pathways by KEGG included DCM and HCM, 
see Fig.5G, H with magenta color highlights on volcano plot and table. Interestingly, when 
normalized to total ErbB2, the ErbB2-Y1006 phosphorylation levels are decreased. On 
the other hand, PTMsigDB pathways analysis did not match any pathways because many 
of those sites are new and not reported in the PTMsigDB database.   
 
Kinase-Substrate Enrichment Analysis (KSEA) Implicated Downregulation of 
MAPK in TgErbB2 and Upregulation of EGFR in R403Q-aMyHCTg  
 
Kinase-Substrate Enrichment Analysis (KSEA) was used to characterize genotype-
induced signaling changes by estimating the kinase's relative activity in TgErbB2 and 
R403Q-aMyHC mice using the global pTyr label-free and TMT quantitative sarcomere 
pTyrosine proteomics data, using their respective Ntg groups as a reference. KSEA 30 is 
a method that infers the kinases' differential activity based on the differential 
phosphorylation of its substrates and computes scores that reflect the directional change 
in each kinase's signaling. This method assumes that the differential activity of kinases is 
correlated with phosphorylation changes in its substrates. A positive score corresponds 
to a kinase with phosphorylated substrates in Tg mice relative to Ntg control. Likewise, a 
negative score is a hypophosphorylation in Tg relative to their Ntg control. The kinase-
substrate interaction data was downloaded from the PhosphoSitePlus (PSP) 31 website. 
Next, the KSEA method was applied to all the pTyr sites identified in these experiments. 
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This resulted in the identification of 27 phosphosites that have associated kinases 
reported on PhosphoSitePlus. However, a total of 58 unique kinases were scored in the 
combined data sets. A KSEA heatmap inferred clusters of kinases downregulated (blue 
color scale) or upregulated (red color scale) is shown in Fig.6A, both TgErbB2 and 
R403Q-aMyHC Tg mice displayed an inferred downregulation of MAP3K6, MAP3K5, and 
MAPK14, whereas TgErbB2 showed an additional downregulation of MAP2K6, MAP2K4, 
TYK2, and RET see highlighted blue rectangle on Fig.6A. Most of them belong to the 
canonical MAPK pathway downstream of k-Ras.  
 On the other hand, R403Q-aMyHC Tg displayed an inferred upregulation of Src, 
LYN, LCK, JAK2, INSR, MAPK1, and HCK, which annotate to Focal Adhesion, VEGF, 
and PDGFR-beta signaling pathways. For example, see the highlighted red rectangle in 
Fig.6A. Altogether these KSEA results suggest that TgErbB2 and R403Q-aMyHC mice 
had a differential kinase activity signature, where TgErbB2 shows downregulation of 
MAPK Pathway and R403Q-aMyHC has an up-regulation of Focal Adhesion, VEGF, and 
PDGFR-beta signaling pathways, which are sharply different cellular responses. 
Since the pathway enrichment analysis of pTyr TMT data did not yield further 
insights distinct from label-free pTyr data, a protein-protein interaction (PPI) network 
approach was employed. Pathway analysis can miss protein groups mainly because 
pathways algorithms are predefined and rigid. PPI might better capture signaling 
responses in these models that are not classically detected by pathway analysis. To do 
so, MoBaS Analysis22,32 was employed, i.e., to identify densely-connected subnetworks 
that are related and might exhibit differential phosphorylation in Tg models. Several 
modules were identified and focus on the top two most statistically significant PPI 
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modules from the label-free data set; for purposes of interpretation, they were designated 
as Module 1 and Module 2. The substrates of Modules 1 and 2 are illustrated in Fig.6B 
and Fig.6D, respectively. Interestingly, PTMsigDB site-level molecular signature analysis 
showed that Module 1 contained site-specific modifications statistically significant for 
Hepatocyte Growth Factor (HGF) perturbation and Thyroid Stimulating Hormone (TSH) 
Pathway (highlighted in light blue). In addition, using MSigDB Gene-Protein Level 
analysis, several pathways, such as the VEGF1/2 pathway, highlighted in yellow in the 
PPI module (Fig.6B, F) showed statistical significance. Also, PTMSigDB analysis for 
Module 2 revealed a significant match with PP2 Perturbation (c-Src family kinases 
inhibitor PP2), which is highlighted in blue in Fig.6D and Fig.6F, and with EGF 
Perturbation (PTMsigDB defines it as a systems biology response to EGF Stimulation). 
Next, KSEA was applied to the identified modules by restricting the analysis to the target 
pTyrosine sites of kinases that are present in the protein-protein interaction Modules 1 
and 2. In Fig.6C, the comparison of kinases altered activity between datasets of Module 
1 substrates is displayed. In this analysis, R403Q-aMyHC mice have a marked significant 
upregulation of PTK6, PTK2, FYN, ABL1, KDR, CSNNK2A1, and AURKB (denoted by 
white asterisk p<0.05), which form part of Integrin Signaling Pathway (ABL1, FYN, PTK2) 
and VEGF Pathway (KDR and PTK2). Likewise, in Module 2 substrates, the kinase 
activity is significantly increased in R403Q-aMyHC mice, see Fig.6E, significant kinases 
denoted by white asterisk (p <0.05). Of note, some of these altered kinases belong to 
Finetti Breast Cancer Kinoma, PDGFR-beta Signaling Pathway, PTP1B Pathway, and 
ErbB2/3 Pathway from MSigDB (See Fig.6E). Altogether these results confirm that 
MoBAS identified functionally relevant modules of protein-protein interactions (PPI) 
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among identified pTyr peptides and pointed insights into system biology processes from 
PTMsigDB that were not detected on global analysis. 
 
 
Tyrphostin AG-825 administration decreased cardiac fibrosis, cardiomyocyte 
disarray and preserved contractile function in the TgErbB2 mouse model 
 
Although TgErbB2 mouse hearts develop a concentric type of HCM, this rapidly 
progresses to pathologic HCM and shows histopathological features of HCM, including 
fibrosis, cardiomyocyte disarray, perturbed Ca2+ handling, arrhythmias, and sudden death 
16.  It was hypothesized that by counteracting the activity of cardiac ErbB2 overexpression 
pharmacologically, a tyrosine kinase receptor, by using AG-825 (an ErbB2 inhibitor), 
would halt the progression of the histopathological phenotype. To that end, TgErbB2 mice 
with established HCM and Ntg controls were treated with AG-825 or DMSO vehicle for 
two weeks, subcutaneously twice daily at a dose of 1mg/Kg 16. Next, myocardial fibrosis 
was evaluated by Masson's trichrome staining. Untreated TgErbB2 mice developed 
variable amounts of fibrosis of the left ventricle (Fig.7A, B, lower left panels); however, 
TgErbB2 treated mice displayed less fibrosis (Fig.7B, lower right panels). 
In contrast, cardiac histology was not affected by AG-825 treatment in Ntg mice. To 
characterize the effects of AG-825 on cardiomyocyte disarray CytoSpectre 33, a web 
graphic user interphase (GUI) was employed, this interphase determines the local 
orientation of structures, including cardiac myocytes, across histological sections, similar 
to the analysis described previously by Seidman Lab 34. Randomly chosen regions of 
interest (ROI) are depicted in Fig.7A and increase the magnification of microphotographs 
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from 5X to 40X (See Fig.7B). The myofiber orientations angle variance was defined is 
referred to as Circular Variance from Ntg treated with the vehicle, see Ntg-Vehicle in 
Fig.7C top left panel, and then compared the cardiac myocytes' orientation angles 
variance from Ntg AG-825 treated (Fig.7C top right panel), which was not significantly 
different (Fig.7D), as described previously 34. In contrast, TgErbB2 mice cardiomyocytes 
treated with the vehicle displayed an orientation angle variance that was significantly 
different from Ntg-Vehicle control; see the heterogeneous and broader shape of the 
orientation plot in Fig. 7C, lower-left panel. Surprisingly, cardiomyocytes from TgErbB2 
mice AG-825 treated displayed significantly less disarray, as demonstrated by the 
significant return of circular variance and shape of the plot to Ntg- Vehicle or AG-825 
treated controls, see Fig.7E. This analysis confirms that cardiomyocytes from TgErbB2 
mice AG-825 treated displayed significantly less myocyte disarray, as indicated by 
reduced circular variance. 
 Lastly, to study the direct in vivo effects of ErbB2 inhibition by AG-825 on 
contractility, echocardiograms, and tissue-doppler imaging (to evaluate diastolic function) 
was performed on conscious mice (non-anesthetized) at baseline and after two weeks of 
treatment. A Vevo 2100 High-Resolution Imaging System with a 40MHz transducer 
(VisualSonics®, Toronto) was used, and the data were subsequently analyzed with an 
Advanced Cardiovascular Package Software. The parameters analyzed were chamber 
dimensions, fractional shortening, ejection fraction, and tissue Doppler velocity dynamics. 
LV functional data obtained by parasternal short-axis echocardiographic imaging 
determined a significant decrease in the mean fractional shortening over time in TgErbB2 
mice treated with vehicle solution compared with the Ntg (Ntg 57.19% ± 2.25 vs. TgErbB2 
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43.72% ±5.05, p-value < 0.05). In contrast, TgErbB2 mice treated with AG-825 did not 
display a significant decline in contractile function over time when compared to Ntg AG-
825 treated (TgErbB2 50.3% ±5.94 vs. Ntg 58.95% ± 2.35, p-value > 0.05). Also, the 
ejection fraction (data not shown) of the TgErbB2 mice treated with the vehicle was 
significantly lower than Ntg (TgErbB2 68.07%±5.64 vs. Ntg 81.60% ± .95); this decline in 
contractility was abolished by AG-825 treatment of ErbB2 Tg mice (TgErbB2 74.86% 
±5.76 vs. Ntg 83.09% ± 1.93). TDI detected no additional beneficial effects on diastolic 
function; see complete Echocardiography data on Supplementary Table 11. Altogether, 
these data suggest that ErbB2 pharmacological inhibition halted or reversed pathological 
remodeling by reducing the fibrotic response and restoring cardiomyocyte alignment, 
further reflected by an in vivo preservation of LV contractile function without effect on LVH 




This study demonstrates that cardiac-specific overexpression of ErbB2 and allelic 
expression of R403Q-αMyHC alters the tyrosine phosphoproteome of the cardiac 
sarcomere and signaling pathways related to hypertrophic cardiomyopathy (HCM). In the 
TgErbB2 mouse model, a total of 51 tyrosine-phosphorylated sites were significantly 
altered, with 28 up-regulated peptides and 23 down-regulated peptides (Log2 FC > 1.0, p 
< 0.05). Among those 51 sites, 7 (Myh6-Y1261, Myh6-Y1349, Ttn-Y2118, Ttn-Y21190, 
Ttn-Y31324, Sgcb-Y46, and ATP2a2-Y497) belong to proteins involved in both the 
hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) KEGG 
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pathways. Significant alterations were observed in the elements of the right ventricular 
cardiomyopathy (ARVC) KEGG pathway. Interestingly, a greater number of tyrosine-
phosphorylated sites were significantly altered in R403Q-αMyHC mice compared to 
TgErbB2 mice (78 vs. 51, respectively; Log2 FC >1.0, p<0.05), including 48 upregulated 
phosphosites and 30 downregulated phosphosites. Conversely, the total number of 
tyrosine-phosphorylated sites identified in both mouse models was similar (TgErbB2 
n=348 vs. R403Q-αMyHC n=352, Fig.2F). This evidence suggests that the differences 
observed can be attributed to genotype or phenotype differences between these two 
mouse models. Interestingly, we unearthed the same HCM/DCM tyrosine-phosphorylated 
peptides in TgErbB2 mice and R403Q-αMyHC mice. However, only on R403Q-αMyHC 
mice, the changes reached statistical significance for HCM/DCM KEGG pathways' 
involvement. Some of the pathways highlighted by the KSEA in R403Q-αMyHC Tg mice 
include the Focal Adhesion, VEGF, ErbB signaling, Chemokine Signaling, and 
Angiopoietin receptor pathways.  
Initially, it was reasoned that overexpression of a receptor tyrosine kinase in 
TgErbB2 mice hearts would result in a more significant alteration of tyrosine 
phosphoproteome. However, the data suggest that a single sarcomere point mutation, as 
in the case of R403Q-αMyHC mice, is enough to alter the cardiac tyrosine 
phosphoproteome significantly. Another surprising finding was that the ErbB signaling 
pathway elements were not significantly altered in TgErbB2 mice, but rather in R403Q-
αMyHC mice. Indeed, MSigDB analysis in the TgErbB2 mice yielded only two targets 
(CRK and SHC1) associated with the ERBB Signaling KEGG pathway. The TgErbB2 
mouse model is important because it shows pronounced cardiac hypertrophy at an early 
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age, sarcomere dysfunction, and abnormal calcium handling 16, thus connecting the 
tyrosine kinase pathway and tyrosine phosphorylation to cardiac hypertrophy. While 
ErbB2 was previously reported to be overexpressed ~40-fold in TgErbB2 hearts 12, the 
tandem mass tagging quantitative proteomics data, which allowed normalization of the 
peptide phosphorylation signal to total protein levels of ErbB2, revealed that the 
phosphorylation level of ErbB2-Y1006 peptide is reduced in this model (Fig.5G). The low 
stoichiometry of phosphorylated:non-phosphorylated ErbB2 may account for the 
apparent lack of alteration of the ErbB signaling pathway. 
In contrast, R403Q-αMyHC exhibited alterations in eight members (CRK, GSK3B, 
MAPK1, MAPK3, NCK1, PTK2, STAT5A, and STAT5B) of the same pathway (Fig.3G). 
The mechanisms by which a pathogenic mutation in the myosin heavy chain may affect 
tyrosine phosphorylation regulation is unknown and warrants further investigation. 
On the other hand, pharmacological inhibition of ErbB2  (HER2/neu) with the 
inhibitor lapatinib in breast cancer patients treated with doxorubicin increases the risk of 
developing heart failure compared to patients treated with doxorubicin alone 35. This 
finding suggests that maintaining homeostasis of tyrosine phosphorylation may be 
important for regulating cardiomyocyte function and homeostasis.  
 
EGFR1 pathway is central to HCM  
The EGFR1 (ErbB1) Pathway seems to play a central role in cardiac hypertrophy in both 
Tg models. However, at the site-specific level, the molecular signature (PTMsigDB) of 
R403Q-αMyHC had 16 specific peptides altered consistent with the activation of the 
EGFR1 pathway. The TgErbB2 mice tyrosine-phosphorylated peptides did not reach 
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statistical significance, with only three specific peptides for PTMsigDB (Fig.3E, G).  EGFR 
pharmacological inhibition, using AG-1478, protects against Angiotensin II-induced 
cardiac hypertrophy in vitro and in vivo 36. The concentric hypertrophy associated with 
ErbB2 cardiac-specific overexpression can be reversed by early administration of 
Lapatinib, which inhibits EGFR receptor Tyrosine kinase 12 in addition to ErbB2.  In this 
study, the ErbB2 receptor's pharmacological blockage by the small molecule inhibitor AG-
825 in TgErbB2 adult mice preserved cardiac function without affecting cardiac 
hypertrophy. In addition, the specific blockage of ErbB2 by AG-825 reduced myocyte 
disarray and cardiac fibrosis. These findings indicate some overlap in cardiac hypertrophy 
signaling mediators downstream of EGFR1 and ErbB2, and the sarcomeric mutation 
R403Q-αMyHC appears to amplify the EGFR Signaling Pathway preferentially.  
 
Tyrosine phosphorylation is present in multiple proteins associated with the 
regulation of cardiac function and disease  
A wide variety of other functionally relevant targets were identified in this study as tyrosine 
phosphorylated, from sarcomere proteins to Z-disk and desmosome components, focal 
adhesion, and adherence junction proteins, membrane receptors, kinases, and 
phosphatases. For instance, tyrosine phosphorylation in several Z-disk associated 
proteins was noted (For a full list, see Supplementary tables 2-7). Z-disk proteins are 
crucial for muscle contraction and mechanical stress, growth, and metabolic signaling 37. 
Also, the alteration in the phosphorylation levels of the desmosome key component 
Plakophilin-2 protein (Pkp2) peptide Pkp2-Y119 was noted in both mouse models, up-
regulation in R403Q-aMyHC Tg and down-regulation in TgErbB2. The functional effect of 
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up- or down-regulation of Pkp2-Y119 phosphorylation is not known. However, Pkp2 
homozygous deletion disrupts heart architecture and is lethal in the embryo 38. In the 
heart, Pkp2 is required for the assembly of the desmosome and the PKC activity 39. 
Autosomal dominant mutations in this gene are responsible for 25% to 50% of 
arrhythmogenic cardiomyopathy (ARVC). Interestingly, TgErbB2 mice have increased 
susceptibility to arrhythmias and myofibrillar disarray 16, similar to patients with myosin 
mutations and HCM. Pkp-Y119 phosphorylation changes could impact the phenotype.  
 
Bioinformatic Identification of Potentially Activated Kinases that are Drug Targets 
The in silico kinase-substrate enrichment analysis (KSEA) implicated a marked 
downregulation of members of canonical MAPK Pathway downstream of k-Ras in 
TgErbB2 mice, whereas, in R403Q-αMyHC mice, an up-regulation of Focal Adhesion, 
VEGF, and PDGFR-beta signaling pathways (SRC, LYN, LCK, JAK2, INSR, MAPK1, and 
HCK) was observed. More importantly, modularity-base scoring (MoBas) analysis 
demonstrated protein-protein interaction networks that by PTMsigDB identified 
Hepatocyte Growth Factor perturbation (or stimulation), PP2 Perturbation (effect of a c-
Src inhibitor), and EGF perturbation (or stimulation). These data demonstrate that many 
targets overlap in both transgenic models of cardiac hypertrophy and although there are 
marked differences in the upstream regulators of ErbB2 and myosin heavy chain, many 
of the downstream effector molecules are common and can be targeted by small-




The MAPK pathway is involved in the adaptive and maladaptive response that could lead 
to heart hypertrophy (for review 40). The RAS-RAF-MEK-ERK signaling pathway is an 
attractive target for therapeutic intervention in oncology, and several selective RAF and 
MEK small molecule inhibitors have been tested in clinical trials 41. The present study 
found increased phosphorylation at MAPK1-Y185, which activates the kinase, in R403Q-
αMyHC, and MAPK1 activity directly relates to heart hypertrophy 42.  c-Src figures as one 
of the potential regulators for the phosphotyrosine proteome changes observed in 
R403Q-αMyHC because it phosphorylates the EGFR receptor upstream and 
phosphorylates Stat, among other targets, downstream. c-Src affects the response to 
mechanical cardiomyocyte stretching by triggering a cascade of intracellular signaling in 
cardiomyocytes towards a hypertrophic response 43,44. Also, c-Src phosphorylates PXN-
Y118 45, and this site had a 25-fold increase in phosphorylation in R403Q-αMyHC mice. 
Interestingly, c-Src mediates the activation of MAPK1 and MAPK3 in response to 
pressure overload 43. Notably, a previous study has shown that pressure overload-
induced cardiac hypertrophy is exacerbated in R403-αMyHC Tg mice 46, suggesting that 
the mechanism by which R403-αMyHC mutation produces heart hypertrophy might be by 
sensitizing cells to pressure-overload induced signaling via c-Src.  
 
R403Q-αMyHC mice displayed enhanced JAK2, STAT5A, and STAT5B phosphorylation 
in the activation sites (Y570, Y694, and Y699, respectively), which indicates not only 
activation of MAPK signaling but also activation of JAK-STAT signaling. Jak-Stat 
Signaling: IL-6 pathway is activated in response to the IL-6 family of cytokines (IL-6, 
cardiotrophin 1, and leukemia inhibitor factor), cross-talks with the EGFR pathway, and is 
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involved in cardiac hypertrophy. This pathway has cardioprotective effects, but chronic 
activation may lead to heart hypertrophy (for review 40). Vakrou et al. performed a pathway 
analysis on miRNA profiles of R403Q-αMyHC. They found similarities with the findings 
described in this work (For IPA data, see Supplementary Fig.S4, Supplementary Table 
9),  such as overactivation of integrin-linked kinase (ILK), IL-8, Rho family GTPase, PAK, 
CXCR4, actin cytoskeleton, and cardiac hypertrophy signaling pathways 47. It is known 
that the integrin-linked kinase signaling pathway is over-activated in heart hypertrophy 48. 
Altogether, these results suggest an essential involvement of Tyrosine phosphorylation 
regulation in myofilaments and other cardiac proteins. The insight gained from these 
studies could inform new therapeutic approaches in sarcomere mutation related HCM as 
well as potentially other conditions associated with HCM. 
 
Limitations & Studies in Perspective 
The studies were limited to two transgenic mouse models that develop cardiac 
hypertrophy; other models of sarcomere mutations or pressure overload such as aortic 
banding could be explored and compared.  Some relevant tyrosine-phosphorylated sites 
might be missed due to their low stoichiometry and technical challenges.  This problem 




This study reveals that altered patterns of Tyrosine phosphorylation are striking in two 
separate models of hypertrophic cardiomyopathy. Moreover, despite some shared sites, 
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etiologically different forms of HCM may harbor specific tyrosine phosphorylation 
signatures. This evidence, combined with inhibition of a specific receptor tyrosine kinase 
using tyrphostin AG-825, can reverse cardiomyocyte disarray, thus preserving function in 
a TgErB2 mouse HCM model, could rationalize approaches to manipulate the Tyr 
phosphoproteome as a therapeutic approach for HCM in general. Furthermore, these 
studies indicate that tyrosine kinase inhibitors, now used broadly in cancer therapies, may 
change cardiac function by directly modifying the heart's tyrosine kinase profile.  
 
METHODS 
Western blot  
Whole heart lysates from Heat Stabilized Tissue were resuspended in 1% SDS buffer, 
10-15 µg were separated by SDS-PAGE, and transferred to nitrocellulose membranes. 
Membranes were blocked with 5% BSA in TBS-T buffer (20 mmol/L Tris pH 7.4, 150 
mmol/L NaCl and 0.05% Tween 20) for 1h at room temperature, then were incubated with 
primary antibody (Anti-pTyr mouse monoclonal 1:2000, Anti-SRC, Anti-pSRC Y416, Anti-
GAPDH 1:1000 dilution, Cell Signaling, Anti-cTnI 1:5000) at 4°C overnight. After washing 
them five times, the secondary antibody (goat anti-mouse-HRP, goat Anti-mouse IRDyeÒ 
800CW or goat Anti-rabbit IRDyeÒ 680 LT 1:10,000) was added and incubated for 45 
min. Then, the membranes were developed with super signal West Pico 
Chemiluminescent Substrate (Thermo), and the immunoreactive bands were detected by 
chemiluminescence system (Bio-Rad) or by Odyssey (Li-Cor). The images were obtained 




Sample Preparation Label-Free: All protocols were performed following the "Guide for 
the Use and Care of Laboratory Animals" published by the National Institutes of Health 
and the Institutional Animal Care and Use Committee's approval. To establish breeding 
colonies, the TgErbB2 and R403Q-αMyHC mice were obtained from Dr. K. Gabrielson 
and Dr. L. A. Leinwand, respectively 16,17. Mice were anesthetized with sodium 
pentobarbital IP (75 mg/kg) or isoflurane (5%) overdose; the hearts were quickly 
dissected, followed by thermal stabilization (Denator T1 Heat Stabilizor, Sweden) and 
stored at -80°C until analyzed. TgErbB2 and R403Q-αMyHC mice hearts (n=5 per group) 
were processed in parallel. To obtain whole heart lysates, cardiac ventricles (~200 mg) 
were homogenized on ice-cold buffer: 20 mM HEPES, pH 7.6, 1mM, 1.5 mM sodium 
pyrophosphate, PhosStop, and 9M urea at 10 μl/mg (wet weight of tissue). The 
homogenate was cooled on ice, followed by brief micro-tip sonication on ice, 
centrifugation at 10,000 × g for 15 min at 4 °C. The supernatant was retrieved, and protein 
concentration was determined by the method of Lowry (Bio-Rad).  
Trypsin Digestion: Protein from heart lysates was reduced in 5 mM of dithiothreitol 
(DTT), 60 °C for 20 minutes, and alkylated in 10 mM iodoacetamide (IDA) at room 
temperature for 15 minutes in the dark. Each sample (30mg per mouse, n=5 mice per 
genotype) was digested with Proteomics grade Trypsin (Promega) at a ratio of 1:200 in 
2M urea, 20mM HEPES buffer, pH 8.0 at room temperature overnight. The digestion was 
terminated with trifluoroacetic acid (1% TFA). Samples were centrifuged (5 min at 1800g), 
and supernatants were desalted by solid-phase extraction (SepPak C18 10cc cartridge, 
Waters). Elutes were lyophilized for three days at -20°C. 
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Enrichment of Tyrosine Phosphopeptides: A total of 150 mg of trypsinized peptides 
per genotype were pooled and enriched for pTyrosine, as previously described 49. 
Lyophilized peptides were mixed in 1.4 ml immunoprecipitation buffer (IAP buffer 50mM 
MOPS, pH 7.2, 10mM sodium phosphate, 50mM NaCl, pH 7.0. A stock solution of protein 
agarose G beads (Santa Cruz Biotechnology) 80μL of slurry were conjugated with 300μg 
of Phospho-Tyrosine Mouse monoclonal antibody (p-Tyr-100, Cell Signaling 
Technology). The beads-Anti-p-Tyr antibody conjugate was transferred to the peptide's 
tube and incubated with gentle rotation for 2h at 4°C. The beads were washed and eluted 
with 55 μl and 45 μl of 0.15% trifluoroacetic acid (TFA), respectively. The two elution 
yields were pooled. The resulting peptide mixtures were purified by solid-phase extraction 
(stage tips C18, Thermo Scientific). The samples were dried by vacuum centrifugation. 
This approach was repeated three times with samples from all three groups run in parallel, 
15 hearts per genotype in three technical replicates. 
 LC-MS/MS Analysis: Phosphopeptides were dissolved in 10μl of 0.1% TFA, 2%ACN 
(v/v) followed by RF-HPLC-ESI-MS/MS analysis. Phosphopeptides were separated on a 
C18 reversed-phase column with a linear gradient of acetonitrile (4−40%) for 120 min and 
then analyzed on an LTQ-Orbitrap Elite MS (ThermoFisher Scientific) with neutro loss 
triggered HCD. 
Peptide Identification, Quantification, and Statistics: Raw MS data were searched 
with Mascot 2.3, and label-free quantification with MS1 extracted ion chromatograms 
were performed using MaxQuant software. For statistical analysis, we followed the 
workflow of Foster et al. 21, with few modifications. First, Partek software was used to 
calculate the p-values, q-values, fold change, and ratio for each peptide intensity. 
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Phosphosites with less than 50% of missing density values were subjected to statistical 
analysis and the reminding missing values were filled with the K-nearest neighbors. Then, 
a normalization of the Log2 densities by median subtraction and determined the fold-
change, ratio, and statistical significance (q and p values), from each of the selected 
phosphosites of the data set. The volcano plots were made with GraphPad Prism 7®. 
Unsupervised principal component analysis (PCA) was used in both data sets separately 
with Partek® software. Data set segregated along with each component concerning the 
pTyr abundance (normalized, mean=0, variance=1). For K-mean clustering and 
unsupervised hierarchical clustering, Spotfire® software was used. 
  
Tandem Mass Tagging Phospho Tyrosine Proteomics 
Sample Preparation and TMT pTyr Enrichment: Myofilament proteins (~7 mg) from 
mouse heart were resuspended in 8 M urea and 50 mM triethylammonium bicarbonate 
(TEAB) (Sigma) followed by reduction with 10 mM dithiothreitol (Sigma) at room 
temperature for 1 h and alkylation with 30 mM iodoacetamide (Sigma) for 20 minutes 
in the dark. The protein samples were then digested overnight at 37 °C using 
sequencing grade trypsin (1:50) (Promega). Tryptic peptides were desalted and labeled 
with 6-plex isobaric tandem mass tags (TMT) (Thermo Scientific) according to 
manufacturer's instructions. The labeling reaction was carried out for 1 hour at room 
temperature, followed by quenching with 100 mM Tris.HCl (pH 8.0). The digested and 
labeled peptides were pooled and desalted with C18 SEP-PAK (Waters), followed by 
pTyrsoine enrichment using PTMScan® Phospho-Tyrosine Rabbit mAb (P-Tyr-1000) kit 
(Cell Signaling Technology). Briefly, the desalted peptides were reconstituted in 1.4 ml 
 31 
of immuno-affinity purification (IP) buffer containing 50 mM MOPS pH 7.2, 10 mM 
sodium phosphate, 50 mM NaCl. Anti-phosphotyrosine antibody (P-Tyr-1000, Cell 
Signaling Technology) was mixed with peptide solution and incubated on a rotator at 
4°C for 2 h. After incubation, the beads were washed with IP buffer and water for two 
and three times, respectively. The phosphotyrosine peptides were eluted using 0.1% 
TFA. The eluted peptide samples were desalted using C18 STAGE tips, vacuum dried, 
and kept at −80°C before LC-MS analysis. From flow-through, a quantification of the full 
proteome was made to serve as a reference for pTyr proteome findings.  
LC-MS/MS Analysis: The phosphotyrosine peptides were analyzed on Orbitrap Fusion 
Lumos Tribrid (Thermo Scientific, San Jose, CA, USA) coupled with Easy-nanoLC 1200 
nanoflow liquid chromatography system (Thermo Scientific). The peptides from each 
fraction were reconstituted in 10% formic acid and loaded on Acclaim PepMap100 
Nano Trap Column (100 μm × 2 cm) (Thermo Scientific) packed with 5 μm C18 particles 
at a flow rate of 5 μl per minute. Peptides were resolved at 250 nl/min flow rate using a 
linear gradient of 10 to 35% solvent B (0.1% formic acid in 95% acetonitrile) over 
95 minutes on the EASY-Spray column (50cm x 75µm ID, PepMap RSLC C18, and 2µm 
C18 particles) (Thermo Scientific) and it was fitted on EASY-Spray ion source that was 
operated at 2.0 kV voltage. Mass spectrometry analysis was carried out in a data-
dependent manner with full scans in the range of m/z 350 to 1500. Both MS and MS/MS 
were acquired and measured using Orbitrap mass analyzer. Full MS scans were 
measured at a resolution of 120,000 at m/z 200. Precursor ions were fragmented using 
a higher-energy collisional dissociation method and detected at a mass resolution of 
30,000 at m/z 200.  
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Peptide search, Identification, and Statistics: MaxQuant 1.5, or the most current 
version, was used for quantitation and identification against a mouse RefSeq database 
(version 78) supplemented with frequently observed contaminants. The search 
parameters used are as follows: a) trypsin as a proteolytic enzyme (with up to two 
missed cleavages) b) peptide mass error tolerance of 10 ppm; c) fragment mass error 
tolerance of 0.02 Da; d) Carbamidomethylation of cysteine (+57.02Da) and TMT tags 
(+229.16 Da) on lysine residue and peptide N-termini as fixed modification and 
oxidation of methionine (+15.99 Da) and phosphorylation of serine/threonine/tyrosine 
(+ 79.96 Da) as variable modifications. Two missed cleavages were allowed and 'match 
between runs' was enabled. Peptides and proteins were filtered at a 1% false discovery 
rate. Proteins with a q-value lower than 0.05 will be considered as differentially 
expressed with statistical significance. In a complementary way, R software was used. 
A two-sided t-test and the moderated p-values and q-values calculation was performed 
using an algorithm developed by Herbrich et al 50. 
Systems Biology Analysis 
Statistical analysis of the label-free data set was performed using Perseus software 51. 
Peptides with less than 50% of detection were filtered and the missing values of the 
intensities of the reminding peptides were filled with k-nearest neighbors. Then, the 
log2 intensities were normalized by mean subtraction subsequently ANOVA and false 
discovery rate calculations. The K-mean clustering with Spotfire, 4 clusters were made 
using correlation as similarity measurement and data centroid based search. A 
heatmap was used to visualize the unsupervised hierarchical clustering of proteins with 
p-value <0.05 by ANOVA test.  
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The web-based software Ingenuity Pathway Analysis (IPA) was used for both data sets 
for pathway analysis. The results obtained were uploaded to IPA software. The Uniprot 
Accession ID was selected as an identifier for each site, and the cut of values for each 
intensity was a p-value < 0.05 and an absolute fold change of 2. Interaction networks 
were generated, including endogenous chemicals with 70 molecules per network and 
25 networks per analysis. All node types and data sources were selected, considering 
all experimentally observed and predicted (high and moderate confidence) in all 
species. 
 
Pathway Enrichment Analysis: The hypergeometric p-value was used to identify the 
processes that are significantly enriched in the proteins and phosphosites that are 
differentially phosphorylated between case and control samples. For this purpose, 
MsigDB 24 was used to analyze the protein level pathways and PTMsigDB 25 to analyze 
the processes at the site level. The population/background for which the enrichment is 
calculated against is restricted to all the proteins in which their sites are quantified in the 
phosphoproteomics experiment, rather than all universally known proteins/phosphosites.  
 
Kinase-Substrate Enrichment Analysis (KSEA): Kinase Substrate Enrichment 
Analysis seeks to identify kinases whose targets exhibit significantly altered 
phosphorylation levels in a given condition. KSEA scores each kinase k with a set of 
substrates S as follows:  
𝑠𝑐𝑜𝑟𝑒(𝑘) = 	
(𝑃,! − 𝑃,) ∗ 	/|𝑆|
𝜎  
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Where, 𝑃,!	Denotes the average log" 𝑓of fold change of all the substrates of kinase k, and 
𝑃, and 𝜎 represent the average and standard deviation of log" 𝑓of fold change of all the 
identified phosphosites in the dataset, respectively. KSEA was performed on the identified 
modules by restricting S to the substrates in the module instead of all substrates in the 
dataset. The data provided by PhosphoSitePLUS 31 was used as the reference for kinase-
substrate associations. This tool is also available to download from 
compbio.case.edu/phosphoxplorer. 
  
Module Identification: First, networks were created in which nodes represent proteins 
and edges represent the protein-protein interaction (PPI) obtained from BioGRID 22,52. 
The proteins were assigned a score in the networks by computing the average fold 
change of phosphosites residing on each protein obtained from experiments individually 
(i.e., Ntg, TgErbB2, and R403Q-aMyHC Tg). Then MoBaS 22 was applied to identify sub-
networks of proteins that are highly connected and differentially phosphorylated. For 
visualization of subnetworks, if a protein in one dataset is not identified in another dataset, 
the node is represented in grey color.  
Echocardiogram: Cardiac morphology and function were assessed by transthoracic 
echocardiography using a high-resolution high-frequency system (Vevo 2100, 
VisualSonics, Canada) equipped with 40 MHz ultrasound probe in conscious mice as 
described previously 22,53. Mechanical and chemical chest hair removal was performed 
by shaving and using a commercially available depilatory agent. Core temperature, 
monitored via a rectal probe, was maintained at 36.5-37ºC using a heating lamp. 
Parasternal long and short-axis views of the heart were captured in both B-and M-modes 
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at optimized frame rates. LV end-diastolic (LVIDd, mm) and end-systolic (LVIDs, mm) 
internal diameters, the end-diastolic wall thickness of both interventricular septum (IVS, 
mm) and LV posterior wall (LVPW, mm), LV ejection fractions (EF, %) and fractional 
shortening (FS, %) were measured using M-Mode in long-axis view. Relative wall 
thickness (RWT), a measure of hypertrophy, was calculated as IVSd+LVPWd/LVID. 
Pulsed-Doppler recordings at the mitral inflow, left ventricular outflow, and basal septum 
was recorded. Digital images were stored and analyzed off-line using commercially 
available Vevo LAB software (VisualSonics, Canada). An experienced echocardiography 
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FIGURES AND FIGURE LEGENDS 
 
Figure 1. Global Tyrosine phosphorylation and c-Src activation is Enhanced in 
Cardiac Hypertrophy associated with ErbB2 overexpression. A) Western Blots show 
increased Tyrosine phosphorylation on TgErbB2 mice heart homogenates (Top Panel). 
Corresponding total protein loading by Coomassie Blue Staining is shown on the lower 
panel. B) Fluorescence densitometry analysis shows that after pTyrosine signal (IRDyeÒ 
800CW) was normalized to total cTnI (IRDyeÒ 680 LT), the TgErbB2 mice had a 
significant increase (2.61±0.22 vs. 1.26±0.2, p<0.05). C) Western Blots show expression 
levels of total Src and p-Src (Tyr 416) and GAPDH as loading control. D), E) Densitometry 
analysis revealed that Src levels are elevated in TgErbB2, and p-Src phosphorylation 
levels are elevated. Signals were normalized to total GAPDH. However, this finding is 


















































Figure 2. Workflow for Global Tyrosine Phosphorylation Profiling by Label-Free 
Proteomics. A) Ventricular tissues were rinsed with PBS and subjected to Heat 
Stabilization using a T1 Tissue Stabilizor (Denator, Sweden) to maximize phosphorylation 
preservation, then snap -frozen in liquid nitrogen and stored at -80°C until further use. B) 














-20°C X 3 days 






















































































Ntg, TgErbB2, and R403Q-aMyHC mice hearts (n=5 per group) were processed in 
parallel to obtain whole heart lysates; 30 mg of protein lysates were used from each 
mouse heart for an in-solution trypsin digestion, a total of 150 mg of trypsinized protein 
per genotype were C18 desalted and lyophilized at –20°C for three days. C) A total of 
150 mg of tryptic peptides (pooled material from 5 hearts per group) were enriched for 
pTyrosine using immunoaffinity precipitation (Protein Agarose Beads + 300 micrograms 
of mAb Anti-pTyr) and desalted on C18 stage tips. D) RP-HPLC ESI (electrospray 
ionization) MS/MS was performed on an LTQ Orbitrap Elite (Thermo Scientific) for a 120 
min on a linear acetonitrile gradient (4−40%). Raw data were searched with Mascot 2.3, 
and label-free quantification with MS1 extracted ion chromatograms were performed 
using MaxQuant. This approach was repeated three times with samples from all three 









Figure 3. PTMSigDB Reveals Distinct Tyrosine Phosphorylation Signatures of 
Cardiac Proteome in Hypertrophic Cardiomyopathy Models. A) Unsupervised 
principal component analysis (PCA) of Non-transgenic, TgErbB2, and R403Q-aMyHC 
mice shows distinct experimental groups' distinct segregation. The full cardiac proteome 














































































Stat5a-Y694-p is phosphorylated in EGFR1 pathway and under EPO Perturbation
Molecular Signature (MSigDB) Gene-Protein Level Molecular Signature (PTMsigDB) Site-Level
Molecular Signature (MSigDB) Gene-Protein Level Molecular Signature (PTMsigDB) Site-Level
Figure 3
 45 
indicate that the groups segregate along with the first principal component (PC #1), which 
accounts for 36.6% of the total correlation in the expression of Phospho Tyrosine 
Proteome (normalized, mean=0, variance=1).  The group of R403Q-aMyHC (red) is the 
most distinct of the three proteomes, whereas the TgErbB2 (blue) and Normal (green) 
heart proteomes differ more marginally. B) A heatmap was used to visualize the 
unsupervised hierarchical clustering of proteins with p-value <0.05 by ANOVA. 
Overrepresented (yellow) and underrepresented (Blue). C) K-means clustering was used 
to parse the phospho-tyrosine proteome by signal intensity into groups whose expression 
changed in TgErbB2 and R403Q-aMyHC relative to the Ntg group. Four clusters were 
made with the proteins that displayed p-value and q-value < 0.05 using correlation as 
similarity measurement, for representation only Cluster 1 (Score:10.47) on the top and 
Cluster 3 (Score: 16.37) on the bottom are shown. D) Volcano plot showing the Log2 fold-
change and –Log10 p-value of each pTyr peptide in the pairwise comparison of Ntg and 
TgErbB2. The dots highlighted in red depict the sites which showed a significantly lower 
intensity, whereas the dots in green highlight the sites with significantly higher intensity 
(p-value <0.05, FC >2). A magnification of the significant sites was made at the figure 
(dotted squares) to label the peptide site. E) Molecular Signature DB (MSigDB) and 
Molecular PTMs Signature DB (PTMsigDB) of Global pTyrosine Phosphorylation data 
identified pathways that were significantly altered.  F) Volcano plot showing the Log2 fold-
change and –Log10 p-value of each pTyr peptide in the pairwise comparison of Ntg and 
R403Q-aMyHC. The dots highlighted in red depict the sites which showed a significantly 
lower intensity, whereas the dots in green highlight the sites with significantly higher 
intensity (p-value <0.05, FC >2). A magnification of the significant sites was made at the 
figure (dotted squares) to label in cyan color for members of EGFR1 Pathway and in 




Figure 4. Workflow for Global Tyrosine Phosphorylation Identification of Normal 
and TgErbB2 Hypertrophic Myofilaments by TMT Quantitative Proteomics. A) 
Myofilament from Ntg (n=3) and ErbB2 (n=3) transgenic mice hearts were freshly isolated 
on ice-cold buffers containing Proteinase and Phosphatase Inhibitors Cocktails (Roche). 
B) All material was resuspended in TEAB, followed by reduction and alkylation. Tryptic 
peptides were desalted and labeled with 6-plex isobaric tandem mass tags (TMT). C) The 
digested and labeled peptides were pooled and desalted with C18 SEP-PAK. The 
enrichment for phosphotyrosine was performed with PTMScan Phospho-Tyrosine Rabbit 
mAb (P-Tyr-1000) kit (Cell Signaling Technology). The eluted peptide samples were 
desalted using C18 STAGE tips D) Easy-nanoLC 1200 nanoflow liquid chromatography 
system coupled to Orbitrap Fusion Lumos Tribrid. 
 
Strategy for Global Tyrosine Phosphoproteome Profiling of Normal and ErbB2Tg 
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Figure 5. TgErbB2 Cardiac Sarcomere pTyrosine Proteome Remodeling. A) Full 
Proteome was labeled with TMT, and the logged and summarized protein signal 
intensities indicate that experimental groups segregate along with the first principal 
component (PC #1), which accounts for 53.9% of the total correlation in the expression 
proteome (normalized, mean=0, variance=1). B) PCA of the phospho-Tyr proteome 
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47.2% of the correlation. C) Signal intensities of the phospho-Tyr proteome were 
normalized to Full Proteome protein expression and analyzed by principal component 
analysis. The distinctive signature of pTyr is still apparent by PC along PC#1 and 
accounts for 57% of the correlation. D) A heatmap was used to visualize the unsupervised 
hierarchical correlation clustering of protein expression and E) pTyr Proteome expression 
with p<0.05 by LIMMA moderated 2-samples t-test comparison of TgErbB2 and Ntg 
group. F) pTyr Phosphopeptides were matched to Proteins identified in the Full Proteome 
set of peptides; the overlap did not vary significantly between matching pTyr Phospho 
peptides to a Protein accession number or a Gene ID (Venn Diagram is shown). G) 
Volcano plot showing the Log2 fold-change and –Log10 p-value of each pTyr peptide in 
the pairwise comparison of Ntg and TgErbB2. The dots highlighted in red depict the sites 
which showed a significantly lower intensity, whereas the dots in green highlight the sites 
with significantly higher intensity (fold-change >0.5, p-value <0.05, and q-value <0.05). 
For clarity of presentation, only some peptides were highlighted. H) Molecular Signature 
DataBase (MSigDB) confirmed targets and the involvement of Dilated and Hypertrophic 









Figure 6. Kinase Substrate Enrichment Analysis & MoBaS Analysis. A) KSEA on 
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results according to normalized scores (i.e., TgErbB2/Ntg, R403Q-aMyHC/Ntg, etc.). 
Only kinases shared between data sets are included, therefore present in Tg and Ntg. 
Asterisks indicate the statistical significance of p <0.05. Red represents a positive score 
and blue a negative score. Red rectangle highlights groups of activated kinases that 
clustered together and are predominant in R403Q-aMyHC, whereas the blue rectangle 
highlights suppressed kinases that clustered and are predominant on TgErbB2. B) 
MoBaS identified a tightly interconnected subnetwork involved in growth factors signaling 
(VEGF1/2 and Hepatocyte Growth Factor). Represented by the top-scoring Protein-
Protein Interaction (PPI) subnetwork called Module 1 was identified on TgErbB2 label-
free and compared to R403Q-aMyHC. C) KSEA on Module 1 group of substrates. D) 
Second top-scoring PPI subnetwork called Module 2 identified on R403Q-aMyHC label-
free and compared to TgErbB2. E) KSEA on Module 2 group of substrates and associated 
pathways and specific kinases are denoted with colored squares. F) Results from 
PTMsigDB and MSigDB analysis. Color code highlight the pathway and the substrate 
involved in the Modules 1 or 2. On PPI modules, each node is a phosphoprotein 
represented by its most significant peptide. Node color is based on Log2 fold-change 






Figure 7.  Tyrosine Kinase receptor Inhibitor AG-825 reduces Cardiac Myocyte 
Disarray and Preserves Contractile Function in TgErbB2 Mice. A) Masson's 
trichrome stained sections (5X) from vehicle-treated Ntg and AG-825–treated Ntg (top 


































































yellow arrowheads point to fibrotic areas. Scale bar 1 mm.  B) Masson's trichrome stained 
sections (40X) from representative regions of interest (ROI) show increased Fibrosis in 
TgErbB2 mice myocardium (Bottom left panel), that fibrosis improved after 2-weeks of 
AG-825 Treatment. The same areas were used to determine the level of cardiac myocyte 
disarray. This was achieved by analyzing cell orientation using CytoSpectre Software 
from Vehicle and AG-825 treated Ntg and TgErbB2 mouse heart sections (scale bar 
50µm). C) Plots of the distribution of cardiac cells orientation angles. Note how Ntg angles 
are homogeneous and did not change in the group treated with AG-825 (Top panel). In 
contrast, Tg treated with vehicle showed less homogenous and different orientation angle, 
which confirms cardiomyocyte disarray (bottom left panel). AG-825 treatment reduces 
cardiomyocyte disarray, and the orientation plot is similar to AG-825 treated NTG group. 
D) Mean orientation angle of cardiac myocytes, and E) Circular variance, another 
measure of isotropy, in Ntg and TgErbB2 mice with and without AG-825 treatment (n= 5 
animals per condition). Graph bars are expressed as mean ± SD; the ANOVA test 
performed statistical comparisons showing a significant improvement of TgErbB2 mice 
treated with AG-825 (p-value<0.05). F) Cardiac echocardiography from the four groups 
demonstrates that AG-825 treatment for 14 days preserved the contractile function, 
estimated as % Fraction Shortening and % Ejection Fraction (not shown), in TgErbB2 
mice (Lower right panel). In contrast, TgErbB2 mice treated with the vehicle deteriorated 
significantly (Lower left panel, paired t-test, p-value<0.05). Ntg mice contractility was not 
affected by vehicle or AG-825 Treatment (Upper Panels). 
 
 
